At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 336 enrolled
Drug / intervention
Influenza vaccine GSK2340272A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunological Equivalence Between GSK2340272A and GSK2340274A Influenza Vaccines in Adults Aged 18 to 60 Years
In Brief
A Phase 3 clinical trial evaluating Influenza vaccine GSK2340272A and Influenza vaccine GSK2340274A for Influenza. Completed, enrolled 336 participants across 7 sites in 2 countries.
Detailed Summary
The primary purpose of the study is to assess the equivalence of the immune response elicited by two GSK Biologicals' adjuvanted influenza investigational vaccines (GSK2340272A and GSK2340274A) in adults aged 18 to 60 years. The second purpose of the study is to evaluate the safety and reactogenicity of these two vaccines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesFrance, Germany
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionNov 2009
Study CompletionNov 2010
TodayJul 2026
First PostedSep 18, 2009
Enrollment StartOct 12, 2009
Primary CompletionNov 9, 2009
Study CompletionNov 4, 2010
TodayJul 2, 2026
Enrollment to primary: 27 daysPosted 16.8 years ago
Interventions
Influenza vaccine GSK2340272Abiological
Two intramuscular injections at Day 0 and Day 21
Influenza vaccine GSK2340274Abiological
Two intramuscular injections at Day 0 and Day 21